A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death

[1] Cheng JW(2010)Updates on cytochrome p450-mediated cardiovascular drug interactions Dis Mon 56 163-79

[2] Frishman WH(2007)Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions Curr Protein Pept Sci 8 619-28

[3] Aronow WS(2007)Cytochrome P450 enzyme isoforms and their therapeutic implications: an update Indian J Med Sci 61 102-16

[4] Jana S(2007)Drugs as CYP3A probes, inducers, and inhibitors Drug Metab Rev 39 699-721

[5] Paliwal J(2008)Inhibition and induction of human cytochrome P450 enzymes: current status Arch Toxicol 82 667-715

[6] Kalra BS(1998)Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes J Clin Pharm Ther 23 403-16

[7] Liu YT(2008)Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 Curr Drug Metab 9 310-22

[8] Hao HP(2007)Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 687-710

[9] Liu CX(2012)Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population Pharmacoepidemiol Drug Saf 21 485-93

[10] Wang GJ(2009)Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy Br J Clin Pharmacol 67 234-41

[1] Cheng JW(2010)Updates on cytochrome p450-mediated cardiovascular drug interactions Dis Mon 56 163-79

[2] Frishman WH(2007)Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions Curr Protein Pept Sci 8 619-28

[3] Aronow WS(2007)Cytochrome P450 enzyme isoforms and their therapeutic implications: an update Indian J Med Sci 61 102-16

[4] Jana S(2007)Drugs as CYP3A probes, inducers, and inhibitors Drug Metab Rev 39 699-721

[5] Paliwal J(2008)Inhibition and induction of human cytochrome P450 enzymes: current status Arch Toxicol 82 667-715

[6] Kalra BS(1998)Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes J Clin Pharm Ther 23 403-16

[7] Liu YT(2008)Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 Curr Drug Metab 9 310-22

[8] Hao HP(2007)Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 687-710

[9] Liu CX(2012)Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population Pharmacoepidemiol Drug Saf 21 485-93

[10] Wang GJ(2009)Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy Br J Clin Pharmacol 67 234-41